Consensus NeuroPace, Inc.

Equities

NPCE

US6412881053

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-03 EDT			5-day change	1st Jan Change
13.64 ^USD	-1.87%		+1.87%	+32.30%

03-15	North American Morning Briefing : Inflation -2-	DJ
03-14	Wells Fargo Upgrades NeuroPace to Overweight From Equalweight, Raises Price Target to $20 From $16	MT

Evolution of the average Target Price on NeuroPace, Inc.

Price target over the last 5 years

History of analyst recommendation changes

71c060de712e1.DEtOLkawzY1s_AbHX11NTDGPV7gg8GfAOxV8bUnsff8.PSQNRxDJg-8-uT-Eamp8NVbCBOBohCD4WFgrJX2_RbBvI3d6BfOp9BSjQw~40a12b14d37cf57c11ada85b43cd72d9

Analyst Recommendations on NeuroPace, Inc.

Wells Fargo Upgrades NeuroPace to Overweight From Equalweight, Raises Price Target to $20 From $16	03-14	MT
JPMorgan Adjusts Price Target on NeuroPace to $17 From $9, Maintains Overweight Rating	03-12	MT
Wells Fargo Increases Price Target on NeuroPace to $16 From $9, Maintains Equalweight Rating	02-22	MT
Leerink Partners Initiates NeuroPace at Outperform Rating With $22 Price Target	01-30	MT
Morgan Stanley Adjusts NeuroPace Price Target to $9 From $8, Maintains Equal Weight Rating	12-04	MT
Morgan Stanley Adjusts Price Target on NeuroPace to $8 From $6, Maintains Equalweight Rating	11-14	MT
Cantor Fitzgerald Starts Coverage on NeuroPace with Overweight Rating, $11 Price Target	11-10	MT
Wells Fargo Adjusts NeuroPace Price Target to $9 From $6, Maintains Equal Weight Rating	23-10-04	MT
Morgan Stanley Upgrades NeuroPace to Equalweight From Underweight, Adjusts Price Target to $6 From $5	23-08-24	MT
Morgan Stanley Adjusts Price Target on NeuroPace to $4.50 From $2.50, Maintains Underweight Rating	23-03-03	MT
Lake Street Initiates NeuroPace at Buy With $10 Price Target	23-02-22	MT
Morgan Stanley Adjusts Price Target on NeuroPace to $2.50 From $3.50, Maintains Underweight Rating	23-01-06	MT
Morgan Stanley Adjusts NeuroPace's Price Target to $3.50 from $5.50, Maintains Underweight Rating	22-10-11	MT
Wells Fargo Adjusts NeuroPace's Price Target to $6 from $9, Keeps Equalweight Rating	22-05-13	MT
Morgan Stanley Lowers NeuroPace's Price Target to $6 From $9, Maintains Underweight Rating	22-05-13	MT
Wolfe Research Starts NeuroPace at Outperform With $13 Price Target	22-04-06	MT
Wells Fargo Adjusts NeuroPace's Price Target to $9 from $11, Keeps Equalweight Rating	22-03-11	MT
SVB Leerink Adjusts NeuroPace's Price Target to $12 from $15, Keeps Outperform Rating	22-03-11	MT
Morgan Stanley Lowers Price Target for NeuroPace to $9 From $12, Maintains Underweight Rating	22-03-11	MT
JPMorgan Lowers Price Target for NeuroPace to $15 From $24, Maintains Overweight Rating	22-03-11	MT
ANALYST RECOMMENDATIONS : Activision Blizzard, Chevron, Exxon Mobil, Gilead, Goldman Sachs...	22-01-19
Wells Fargo Downgrades NeuroPace to Equalweight From Overweight; Price Target is $11	22-01-19	MT
Morgan Stanley Cuts NeuroPace to Underweight From Equalweight, Price Target to $12 From $17	22-01-07	MT
Wells Fargo Adjusts Price Target on NeuroPace to $20 From $28, Reiterates Overweight Rating	21-11-11	MT
NEUROPACE : Baird Starts NeuroPace at Outperform With $26 Price Target	21-08-18	MT